Ensem Therapeutics patents new GTPase KRAS mutant inhibitors
Ensem Therapeutics Inc. has disclosed new tetracyclic GTPase KRAS mutant inhibitors, particularly G12V mutant inhibitors, potentially useful for the treatment o...
Ensem Therapeutics Inc. has disclosed new tetracyclic GTPase KRAS mutant inhibitors, particularly G12V mutant inhibitors, potentially useful for the treatment of cancer.